4D Molecular Therapeutics, Inc. (FDMT) Form 10-Q — Aug 13, 2026
4D Molecular Therapeutics reported a Q2 2026 net loss of $72.9 million ($1.04 per share), up 33% from $54.7 million a year ago, as R&D spending jumped 42% to $68.3 million on wet AMD Phase 3 activity. First-half net loss widened 38% to $141.7 million. The company held $430.6 million in cash, cash equivalents and marketable securities at June 30, 2026, supported by a $20 million draw on a new $200 million Hercules Capital loan facility maturing June 1, 2031 and $31.6 million of at-the-market equity sales in the half.
Key figures
- Revenue
- 3781000
- Total Debt
- 20000000
- Debt Amount
- 20000000
- Total Assets
- 492615000
- Cash Position
- 70372000
- Interest Rate
- 8.75% (effective 10.64%) on the initial $20.0M Hercules borrowing
- Maturity Date
- June 1, 2031
- Shares Outstanding
- 55244211
- H1 2026 Rn D
- 133262000
- Q2 2026 Rn D
- 68282000
- H1 2026 Revenue
- 6828000
- Cff Initial Tranche
- 7500000
- Accumulated Deficit
- 858000000
- Stockholders Equity
- 407659000
- Atm Shares Sold H1 2026
- 3518472
- Cff Additional Funding
- 11000000
- Atm Net Proceeds H1 2026
- 31600000
- Hercules Facility Total
- 200000000
- Otsuka Upfront Received
- 85000000
- Pre Funded Warrant Shares
- 16935665
- Hercules Undrawn Tranche1
- 30000000
- 4 FRONT1 Patients Randomized
- 523
- Otsuka Milestones Potential
- 335500000
- Otsuka Collaboration Receivable
- 4600000
- Remaining Performance Obligations
- 33400000
- Total Cash And Marketable Securities
- 430600000
Price after filing
Close on the filing date to close N calendar days later (from $11.65). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.